Actuate Therapeutics Joining Lantern Pharma Webinar
Actuate Therapeutics, Inc. (NASDAQ: ACTU) is gearing up for an engaging webinar hosted by Lantern Pharma. In this exciting session, the company plans to delve into how Lantern's innovative AI platform is being utilized to identify and develop biomarkers for elraglusib, Actuate's lead investigational drug.
Webinar Details and Key Speakers
The webinar, titled "Webinar Wednesday," is set to take place soon. Key speakers Andrew Mazar, Ph.D., Chief Operating Officer of Actuate Therapeutics, and Joseph McDermott, Ph.D., Lantern's computational biologist, will be at the forefront of the discussion.
Focus on Research Collaboration
During the session, both experts will shed light on their ongoing collaboration aimed at accelerating the development of elraglusib. This partnership promises not only to advance this drug candidate but also to enhance the identification of additional biomarkers that are critical for understanding the drug's therapeutic action and overall effectiveness in clinical settings.
How to Register for the Webinar
For those interested in attending this informative event, registration is straightforward. Attendees can easily sign up through the event's official registration page. Don’t miss the chance to learn about the merging of artificial intelligence and biopharmaceuticals in potentially revolutionizing cancer treatment.
The Innovative Role of Elraglusib
Elraglusib is making waves as a promising new GSK-3? inhibitor currently undergoing rigorous evaluations in clinical trials. Its primary focus is on treating metastatic pancreatic cancer and other difficult-to-treat cancers, showcasing its potential to tackle significant challenges faced in oncology.
Clinical Trials Overview
This investigational drug is typically involved in Phase 2 trials for pancreatic cancer and Phase 1/2 trials for Ewing Sarcoma and related conditions. These clinical trials are crucial steps in determining both the efficacy and safety of elraglusib, as they utilize innovative approaches to generate meaningful outcomes for patients.
About Actuate Therapeutics
Actuate Therapeutics is at the forefront of developing groundbreaking treatments for high-impact cancers. The company aims to target complex molecular pathways that contribute to tumor growth and resistance to existing therapies. Elraglusib is designed to inhibit key pathways associated with chemoresistance, thus aiming to enhance treatment responses.
Immune System Interaction
Interestingly, elraglusib not only attacks cancer pathways but also aids in mediating anti-tumor immunity. It achieves this through the regulation of immune responses, thereby enabling a holistic approach to the treatment of cancer patients who often face limited options.
Contact for More Information
To learn more about Actuate Therapeutics, interested parties can reach out to their Investor Contact:
Mike Moyer
Managing Director
LifeSci Advisors, LLC
Email: mmoyer@lifesciadvisors.com
Frequently Asked Questions
What is the focus of the upcoming webinar?
The webinar will focus on how Lantern's AI platform is utilized in drug development, specifically for Actuate's elraglusib.
Who will be speaking at the webinar?
Andrew Mazar, Ph.D., from Actuate Therapeutics, and Joseph McDermott, Ph.D., from Lantern Pharma, are the key speakers.
What is elraglusib?
Elraglusib is a GSK-3? inhibitor being investigated for the treatment of various cancers, including pancreatic cancer and Ewing Sarcoma.
How can I register for the webinar?
Registration is available through the official webinar link, which can be accessed easily online.
Where can I find more information about Actuate Therapeutics?
More information can be found on Actuate Therapeutics' official website.
